S&P lifts U.S. Renal to stable

Standard & Poor’s said it revised the outlook on U.S. Renal Care Inc. to stable from negative.

The agency also said it affirmed the company’s B corporate credit rating.1

S&P also said it affirmed the company’s B rating on the company’s first-lien debt and CCC+ on the second-lien debt. The 3 and 6 recovery ratings, respectively, are unchanged.

The ratings reflect the company’s narrow business focus and reimbursement risk, the agency said.

The ratings also consider the company’s financial risk profile with leverage expected to remain at more than 6x over the next year, S&P said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.